Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.40 |
| ▸ | TDO2 | P48775 | 3/20 | 0.40 |
| ▸ | RARA | P10276 | 2/20 | 0.40 |
| ▸ | RARB | P10826 | 2/20 | 0.40 |
| ▸ | RARG | P13631 | 2/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MLYCD | O95822 | 3/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14703271 | 0.93 | HDAC6 (0.48) | IDO1TDO2RARARARBRARG | |
| SCHEMBL12973012 | 0.80 | IDO1 (0.36) | IDO1TDO2RARARARBRARG | |
| SCHEMBL12973017 | 0.80 | RARA (0.46) | IDO1TDO2RARARARBRARG | |
| SCHEMBL12973015 | 0.76 | PTGS2 (0.54) | IDO1TDO2PTGS2PTGDR2 | |
| SCHEMBL12973020 | 0.76 | IDO1 (0.42) | IDO1TDO2KDM4EALDH1A1PTGS2 | |
| SCHEMBL14705439 | 0.71 | MAP2K4 (0.38) | CES1MAP2K4HDAC6HDAC1KDM4E | |
| SCHEMBL19056956 | 0.71 | CES1 (0.65) | CES1MAP2K4HDAC6HDAC1MLYCD | |
| SCHEMBL12992938 | 0.69 | IDO1 (0.38) | IDO1TDO2ALDH1A1 | |
| SCHEMBL13639889 | 0.68 | PTGS2 (0.49) | IDO1TDO2PTGS2PTGDR2 | |
| SCHEMBL12973037 | 0.67 | HDAC6 (0.63) | CES1HDAC6HDAC1MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859717-B2 | Nitrogen-containing fused ring compound, nitrogen-containing fused ring polymer, organic thin film, and organic thin film element | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-10-14 | — | — | US | disclosed |
| US-8378338-B2 | Conjugated compound, nitrogenated condensed-ring compound, nitrogenated condensed-ring polymer, organic thin film, and organic thin film element | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-02-19 | — | — | US | disclosed |
| US-8378338-B2 | Conjugated compound, nitrogenated condensed-ring compound, nitrogenated condensed-ring polymer, organic thin film, and organic thin film element | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20130041123-A1 | NITROGEN-CONTAINING FUSED RING COMPOUND, NITROGEN-CONTAINING FUSED RING POLYMER, ORGANIC THIN FILM, AND ORGANIC THIN FILM ELEMENT | OSAKA UNIVERSITY (JP) | 2013-02-14 | — | — | US | disclosed |
| US-20100301314-A1 | CONJUGATED COMPOUND, NITROGENATED CONDENSED-RING COMPOUND, NITROGENATED CONDENSED-RING POLYMER, ORGANIC THIN FILM, AND ORGANIC THIN FILM ELEMENT | OSAKA UNIVERSITY (JP) | 2010-12-02 | — | — | US | disclosed |
| US-20100301314-A1 | CONJUGATED COMPOUND, NITROGENATED CONDENSED-RING COMPOUND, NITROGENATED CONDENSED-RING POLYMER, ORGANIC THIN FILM, AND ORGANIC THIN FILM ELEMENT | OSAKA UNIVERSITY (JP) | 2010-12-02 | — | — | US | disclosed |
| EP-2223918-A1 | CONJUGATED COMPOUND, NITROGENATED CONDENSED-RING COMPOUND, NITROGENATED CONDENSED-RING POLYMER, ORGANIC THIN FILM, AND ORGANIC THIN FILM ELEMENT | Osaka University (JP) | 2010-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130041123-A1 | NITROGEN-CONTAINING FUSED RING COMPOUND, NITROGEN-CONTAINING FUSED RING POLYMER, ORGANIC THIN FILM, AND ORGANIC THIN FILM ELEMENT | NOM1, NOS1, MNS1 | IDO1 1349/4885TDO2 641/4885RARA 4299/4885 |
| US-20100301314-A1 | CONJUGATED COMPOUND, NITROGENATED CONDENSED-RING COMPOUND, NITROGENATED CONDENSED-RING POLYMER, ORGANIC THIN FILM, AND ORGANIC THIN FILM ELEMENT | F12, F9, C9 | IDO1 1674/4885TDO2 347/4885RARA 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.